News + Filings Transactions Holdings
All 13F 13D/G Other
|
Cormorant Asset Management, LP
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
04/24/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
03/13/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 17.7% stake in Ambrx Biopharma Inc. |
02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 8.4% stake in Elevation Oncology, Inc. |
02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 9.2% stake in Design Therapeutics, Inc. |
02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 6.1% stake in GreenLight Biosciences Holdings, PBC |
02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 8.7% stake in Immuneering Corporation |
02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 6% stake in Ambrx Biopharma Inc. |
02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 6% stake in Monte Rosa Therapeutics, Inc. |
02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 8% stake in BioAtla, Inc. |
02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 8% stake in Aerovate Therapeutics, Inc. |
02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 6.8% stake in Cabaletta Bio, Inc. |
02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 4.7% stake in Arcellx, Inc. |
02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 5.2% stake in Olema Pharmaceuticals, Inc. |
02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 5.3% stake in Altimmune, Inc. |
02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 2.7% stake in Viridian Therapeutics, Inc. |
02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 10% stake in Longboard Pharmaceuticals, Inc. |
02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 6.5% stake in Tarsus Pharmaceuticals, Inc. |
02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 6.3% stake in Astria Therapeutics, Inc. |
02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 4% stake in VectivBio Holding AG |
02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 4.7% stake in Tango Therapeutics, Inc. |
02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 4.5% stake in Prometheus Biosciences, Inc. |
02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 10% stake in Eledon Pharmaceuticals, Inc. |
02/14/2022 |
SC 13G/A
| Cormorant Asset Management, LP reports a 10% stake in Longboard Pharmaceuticals, Inc. |
02/14/2022 |
SC 13G/A
| Cormorant Asset Management, LP reports a 4.8% stake in Prometheus Biosciences, Inc. |
02/14/2022 |
SC 13G/A
| Cormorant Asset Management, LP reports a 4% stake in Galecto, Inc. |
02/14/2022 |
SC 13G/A
| Cormorant Asset Management, LP reports a 9.8% stake in Forma Therapeutics Holdings, Inc. |
02/14/2022 |
SC 13G/A
| Cormorant Asset Management, LP reports a 4.1% stake in Cabaletta Bio, Inc. |
02/14/2022 |
SC 13G/A
| Cormorant Asset Management, LP reports a 0% stake in C4 Therapeutics Holdings, Inc. |
02/14/2022 |
SC 13G/A
| Cormorant Asset Management, LP reports a 7.5% stake in Aerovate Therapeutics, Inc. |
02/14/2022 |
SC 13G/A
| Cormorant Asset Management, LP reports a 3.3% stake in Revolution Medicines, Inc. |
02/14/2022 |
SC 13G/A
| Cormorant Asset Management, LP reports a 7.1% stake in Ambrx Biopharma Inc. |
02/14/2022 |
SC 13G/A
| Cormorant Asset Management, LP reports a 6.5% stake in Monte Rosa Therapeutics, Inc. |
02/14/2022 |
SC 13G/A
| Cormorant Asset Management, LP reports a 9.8% stake in Design Therapeutics, Inc. |
02/14/2022 |
SC 13G/A
| Cormorant Asset Management, LP reports a 5.8% stake in BioAtla, Inc. |
|
|
|